JP2021523126A5 - - Google Patents
Info
- Publication number
- JP2021523126A5 JP2021523126A5 JP2020561795A JP2020561795A JP2021523126A5 JP 2021523126 A5 JP2021523126 A5 JP 2021523126A5 JP 2020561795 A JP2020561795 A JP 2020561795A JP 2020561795 A JP2020561795 A JP 2020561795A JP 2021523126 A5 JP2021523126 A5 JP 2021523126A5
- Authority
- JP
- Japan
- Prior art keywords
- months
- composition according
- accumulated
- pathological tau
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666459P | 2018-05-03 | 2018-05-03 | |
| US62/666,459 | 2018-05-03 | ||
| PCT/US2019/030184 WO2019213245A1 (en) | 2018-05-03 | 2019-05-01 | Methods for reducing accumulated pathologic tau protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523126A JP2021523126A (ja) | 2021-09-02 |
| JP2021523126A5 true JP2021523126A5 (https=) | 2022-05-10 |
Family
ID=66530499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561795A Pending JP2021523126A (ja) | 2018-05-03 | 2019-05-01 | 蓄積した病理学的Ｔａｕタンパク質を低減する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210137861A1 (https=) |
| EP (1) | EP3787750A1 (https=) |
| JP (1) | JP2021523126A (https=) |
| WO (1) | WO2019213245A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021522282A (ja) | 2018-04-27 | 2021-08-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | リソソーム蓄積障害の治療 |
| US12076330B2 (en) | 2018-04-27 | 2024-09-03 | The Regents Of The University Of California | Inhibition of lipofuscin aggregation by molecular tweezers |
| KR20220145861A (ko) * | 2020-02-24 | 2022-10-31 | 오블라토 인코포레이티드 | 암 및 종양을 치료하기 위한 조성물 및 방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2270421T3 (es) * | 1993-12-21 | 2007-04-01 | Innogenetics N.V. | Anticuerpos monoclonales especificos para phf-tau, hibridomas que secretan los mismos, reconocimiento de antigeno por estos anticuerpos y sus aplicaciones. |
| US5488145A (en) * | 1993-12-23 | 1996-01-30 | Oklahoma Medical Research Foundation | 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps |
| AU2003291358A1 (en) * | 2002-11-07 | 2004-06-03 | Molecular Geriatrics Corporation | Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease |
| EP2470015B1 (en) * | 2009-08-24 | 2016-01-13 | Hough Ear Institute | Nitrone compounds for treating sensorineural hearing loss |
| ES2893825T3 (es) * | 2011-02-04 | 2022-02-10 | Hough Ear Inst | Métodos de tratamiento de lesiones cerebrales |
| EP2764863B1 (en) * | 2011-10-03 | 2020-03-11 | National Center for Geriatrics and Gerontology | Tau aggregation inhibitor |
| US20180256756A1 (en) * | 2015-09-18 | 2018-09-13 | Oklahoma Medical Research Foundation | Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier |
| US10576125B2 (en) * | 2016-10-31 | 2020-03-03 | Hough Ear Institute | Methods for enhancing synaptogenesis and neuritogenesis |
-
2019
- 2019-05-01 EP EP19723991.6A patent/EP3787750A1/en not_active Withdrawn
- 2019-05-01 JP JP2020561795A patent/JP2021523126A/ja active Pending
- 2019-05-01 US US17/052,093 patent/US20210137861A1/en active Pending
- 2019-05-01 WO PCT/US2019/030184 patent/WO2019213245A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523126A5 (https=) | ||
| Roberts et al. | Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis | |
| Molinuevo et al. | Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias | |
| JP2019537582A5 (https=) | ||
| Bates et al. | Ototoxicity induced by gentamicin and furosemide | |
| Kornblut et al. | Ear disease in patients with Wegener's granulomatosis | |
| JP2011527339A5 (https=) | ||
| JP2025060686A5 (https=) | ||
| JP2005504804A5 (https=) | ||
| JP2019524834A5 (https=) | ||
| JP2018514510A5 (https=) | ||
| JP2025508004A5 (https=) | ||
| JP2015523346A5 (https=) | ||
| JP2024516795A5 (https=) | ||
| JP2024512425A5 (https=) | ||
| WO2008021970A3 (en) | Treatment of motor neuron disease, including certain neurological disorders, motor neuropathies and chronic inflammatory diseases | |
| JP2021529829A5 (https=) | ||
| ES2534553T3 (es) | Formulaciones y métodos para tratar la amiloidosis | |
| US11690830B2 (en) | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | |
| JP2018512451A5 (https=) | ||
| US20250000795A1 (en) | Treatment of sepsis and septic shock | |
| JP2020504154A5 (https=) | ||
| JP2021522241A5 (https=) | ||
| JP2023520703A5 (https=) | ||
| CN102716123A (zh) | 一种用于治疗IgA肾病复方制剂 |